The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma

Epigenetics

Volumn 6, Issue 8, 2011, Pages 1029-1034

  Nelson, Heather H ^a,b   Almquist, Lindsay M ^a,b   LaRocca, Jessica L ^a   Plaza, Silvia L ^c   Lambert Messerlian, Geralyn ^c   Sugarbaker, David J ^c   Bueno, Raphael ^d   Godleski, John J ^d   Marsit, Carmen J ^e   Christensen, Brock C ^c   Kelsey, Karl T ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c BROWN UNIVERSITY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Mesothelioma; Methylation; MSLN; Screening; SMRP

Indexed keywords

BISULFITE; MESOTHELIN; SOLUBLE MESOTHELIN RELATED PEPTIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CPG ISLAND; DNA METHYLATION; EPIGENETICS; FEMALE; GENE; GENE SILENCING; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MSLN GENE; PLEURA MESOTHELIOMA; PROTEIN BLOOD LEVEL; TRANSCRIPTION INITIATION SITE;

EID: 79961213442     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.6.8.16074     Document Type: Article

References (23)

1. Price B, Ware A. Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology and End Results Program data for 1973 through 2003. Am J Epidemiol 2004; 159:107-12.
2. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999; 79:666-72.
3. Gaafar RM, Eldin NH. Epidemic of mesothelioma in Egypt. Lung Cancer 2005; 49:17-20.
4. Musk AW, de Klerk NH. Epidemiology of malignant mesothelioma in Australia. Lung Cancer 2004; 45:21-3.
5. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353:1591-603.
6. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas and ovarian cancers. Proc Natl Acad Sci USA 1996; 93:136-40.
7. Beyer HL, Geschwindt RD, Glover CL, Tran L, Hellstrom I, Hellstrom KE, et al. MESOMARK: a potential test for malignant pleural mesothelioma. Clin Chem 2007; 53:666-72.
8. Di Serio F, Fontana A, Loizzi M, Capotorto G, Maggiolini P, Mera E, et al. Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results. Clin Chem Lab Med 2007; 45:634-8.
9. Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008; 85:265-72.
10. Scherpereel A, Grigoriu B, Conti M, Gey T, Gregoire M, Copin MC, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006; 173:1155-60.
11. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007; 13:2928-35.
12. Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, de Klerk N, et al. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 2007; 132:1239-46.
13. Cristaudo A, Foddis R, Vivaldi A, Guglielmi G, Dipalma N, Filiberti R, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007; 13:5076-81.
14. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, et al. Soluble mesothelin-related protein- a blood test for mesothelioma. Lung Cancer 2005; 49:109-11.
15. Christensen B, Houseman EA, Godleski JJ, Marsit CJ, Longacker JL, Roelofs CR, et al. Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Res 2009; 69:227-34.
16. Destro A, Ceresoli GL, Baryshnikova E, Garassino I, Zucali PA, De Vincenzo F, et al. Gene methylation in pleural mesothelioma: correlations with clinicopathological features and patient's follow-up. Lung Cancer 2008; 59:369-76.
17. Goto Y, Shinjo K, Kondo Y, Shen L, Toyota M, Suzuki H, et al. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res 2009; 69:9073-82.
18. Cristaudo A, Foddis R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, et al. Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein. Occup Environ Med 2010; 67:233-6.
19. Applebaum KM, Furniss CS, Zeka A, Posner MR, Smith JF, Bryan J, et al. Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer. J Natl Cancer Inst 2007; 99:1801-10.
20. Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol 2008; 3:1317-24.
21. Tan K, Kajino K, Momose S, Masaoka A, Sasahara K, Shiomi K, et al. Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter. Hum Pathol 2010; 41:1330-8.
22. Obulhasim G, Fujii H, Matsumoto T, Yasen M, Abe M, Matsuoka S, et al. Mesothelin gene expression and promoter methylation/hypomethylation in gynecological tumors. Eur J Gynaecol Oncol 2010; 31:63-71.
23. Sato N, Maitra A, Fukushima N, van Heek NT, Matsubayashi H, Iacobuzio-Donahue CA, et al. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res 2003; 63:4158-66.